According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 26.09.2023 9371362-00007 Date of first issue: 27.08.2021 5.1

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name Sitagliptin / Simvastatin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

: Pharmaceutical Use of the Sub-

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company **MSD**

120 Moorgate

EC2M 6UR London, United Kingdom

Telephone : +44 (0) 2081548000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Eye irritation, Category 2 H319: Causes serious eye irritation.

H317: May cause an allergic skin reaction. Skin sensitisation, Category 1 Specific target organ toxicity - repeated H373: May cause damage to organs through pro-

longed or repeated exposure. exposure, Category 2

Long-term (chronic) aquatic hazard, Cat-H412: Harmful to aquatic life with long lasting ef-

egory 3 fects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 20.03.2023

 5.1
 26.09.2023
 9371362-00007
 Date of first issue: 27.08.2021

Hazard pictograms :





Signal word : Warning

Hazard statements : H317 May cause an allergic skin reaction.

H319 Causes serious eye irritation.

H373 May cause damage to organs through prolonged or

repeated exposure.

H412 Harmful to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P260 Do not breathe dust.

P273 Avoid release to the environment.

P280 Wear protective gloves/ eye protection/ face protection.

Response:

P314 Get medical advice/ attention if you feel unwell. P333 + P313 If skin irritation or rash occurs: Get medical

advice/ attention.

P337 + P313 If eye irritation persists: Get medical advice/

attention.

Hazardous components which must be listed on the label:

Simvastatin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Sitagliptin	654671-77-9	Eye Irrit. 2; H319	>= 10 - < 20
Simvastatin	79902-63-9	Skin Irrit. 2; H315 Skin Sens. 1; H317 STOT RE 1; H372 (Liver, muscle, optic nerve, Eye) Aquatic Chronic 2; H411	>= 2.5 - < 10

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 20.03.2023

 5.1
 26.09.2023
 9371362-00007
 Date of first issue: 27.08.2021

Substances with a workpla	ace exposure limit :	
Cellulose	9004-34-6	>= 1 - < 10
	232-674-9	
Starch	9005-25-8	>= 1 - < 10
	232-679-6	
Ascorbic acid	50-81-7	>= 1 - < 10
	200-066-2	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause an allergic skin reaction.

Causes serious eye irritation.

May cause damage to organs through prolonged or repeated

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 5.1 26.09.2023 9371362-00007 Date of first issue: 27.08.2021

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Metal oxides

Oxides of phosphorus

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060).

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 5.1 26.09.2023 9371362-00007 Date of first issue: 27.08.2021

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres. Use only with adequate ventilation.

Local/Total ventilation

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust. Do not swallow.

Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage : Keep in properly labelled containers. Store in accordance with

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 20.03.2023

 5.1
 26.09.2023
 9371362-00007
 Date of first issue: 27.08.2021

areas and containers the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

dust of any kind 10 mg/m3

Value type (Form of exposure): TWA (Inhalable)

Basis: GB EH40

4 mg/m3

Value type (Form of exposure): TWA (Respirable fraction)

Basis: GB EH40

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Sitagliptin	654671-77- 9	TWA	0.5 mg/m3 (OEB 2)	Internal
Cellulose	9004-34-6	TWA (inhalable dust)	10 mg/m3	GB EH40
		TWA (Respirable dust)	4 mg/m3	GB EH40
		STEL (inhalable dust)	20 mg/m3	GB EH40
Simvastatin	79902-63-9	TWA	25 μg/m3 (OEB 3)	Internal
	Further information: DSEN			
		Wipe limit	250 µg/100 cm ²	Internal
Starch	9005-25-8	TWA (inhalable dust)	10 mg/m3	GB EH40
		TWA (Respirable dust)	4 mg/m3	GB EH40
Ascorbic acid	50-81-7	TWA	5000 μg/m3 (OEB 1)	Internal

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 20.03.2023

 5.1
 26.09.2023
 9371362-00007
 Date of first issue: 27.08.2021

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices)

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to BS EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : powder Colour : pink

Odour : No data available
Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Upper explosion limit / Upper

flammability limit

No data available

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 20.03.2023

 5.1
 26.09.2023
 9371362-00007
 Date of first issue: 27.08.2021

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility
Partition coefficient: n-

octanol/water

No data available Not applicable

Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available

Molecular weight : No data available

Particle size : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 20.03.2023

 5.1
 26.09.2023
 9371362-00007
 Date of first issue: 27.08.2021

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of : Inhalation exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Sitagliptin:

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg

LD50 (Mouse): 3,000 mg/kg

Simvastatin:

Acute oral toxicity : LD50 (Rat): 5,000 mg/kg

LD50 (Mouse): 3,800 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Ascorbic acid:

Acute oral toxicity : LD50 (Rat): 11,900 mg/kg

Skin corrosion/irritation

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 20.03.2023

 5.1
 26.09.2023
 9371362-00007
 Date of first issue: 27.08.2021

Components:

Sitagliptin:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Simvastatin:

Species : Rabbit

Remarks : Moderate skin irritation

Ascorbic acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Sitagliptin:

Species : Rabbit
Method : Draize Test
Result : Irritating to eyes.

Simvastatin:

Species : Rabbit Remarks : slight irritation

Starch:

Species : Rabbit

Result : No eye irritation

Ascorbic acid:

Species : Rabbit

Method : OECD Test Guideline 405

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 20.03.2023

 5.1
 26.09.2023
 9371362-00007
 Date of first issue: 27.08.2021

Components:

Sitagliptin:

Test Type : Local lymph node assay (LLNA)

Species : Mouse

Method : OECD Test Guideline 429
Result : Not a skin sensitizer.

Simvastatin:

Assessment : Probability or evidence of skin sensitisation in humans

Result : positive

Starch:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Ascorbic acid:

Test Type : Maurer optimisation test

Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Sitagliptin:

Genotoxicity in vitro : Test Type: Ames test

Result: negative

Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro) Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Simvastatin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 5.1 26.09.2023 9371362-00007 Date of first issue: 27.08.2021

Test Type: Alkaline elution assay

Result: negative

Test Type: Chromosomal aberration

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Ascorbic acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 5.1 26.09.2023 9371362-00007 Date of first issue: 27.08.2021

Carcinogenicity

Not classified based on available information.

Components:

Sitagliptin:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Rat

Application Route : oral (drinking water)

Exposure time : 2 Years
Result : positive
Target Organs : Liver

Remarks : Significant toxicity observed in testing

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

Simvastatin:

Species : Mouse
Application Route : Oral
Exposure time : < 92 weeks
Target Organs : Harderian gland
Tumor Type : Liver, Lungs

Remarks : The significance of these findings for humans is not certain.

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Tumor Type : Liver, Thyroid

Remarks : The significance of these findings for humans is not certain.

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Ascorbic acid:

Species : Mouse
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Reproductive toxicity

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 5.1 26.09.2023 9371362-00007 Date of first issue: 27.08.2021

Components:

Sitagliptin:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL Parent: 1,000 mg/kg body weight Result: Animal testing did not show any effects on fertility.

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Teratogenicity: LOAEL: 250 mg/kg body weight

Result: Embryotoxic effects and adverse effects on the off-

spring were detected., No teratogenic effects

Test Type: Embryo-foetal development

Species: Rabbit

Teratogenicity: NOAEL: 125 mg/kg body weight

Result: No teratogenic effects

Simvastatin:

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral

Fertility: LOAEL: 25 mg/kg body weight

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Embryo-foetal toxicity: NOAEL: 25 mg/kg body weight Result: No teratogenic effects, No adverse effects

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Oral

Embryo-foetal toxicity: NOAEL: 10 mg/kg body weight Result: No teratogenic effects, No adverse effects

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Embryo-foetal toxicity: LOAEL: 60 mg/kg body weight

Result: Teratogenic potential

Remarks: Based on data from similar materials

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 5.1 26.09.2023 9371362-00007 Date of first issue: 27.08.2021

Effects on foetal develop-

ment

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Ascorbic acid:

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Simvastatin:

Target Organs : Liver, muscle, optic nerve, Eye

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Sitagliptin:

Species : Mouse
NOAEL : 500 mg/kg
LOAEL : 1,000 mg/kg

Application Route : Oral
Exposure time : > 2 yr
Target Organs : Kidney

Species : Rat

NOAEL : 500 mg/kg LOAEL : 1,000 mg/kg

Application Route : Oral Exposure time : 14 Weeks

Target Organs : Liver, Kidney, Heart, Teeth

Species : Dog
NOAEL : 10 mg/kg
LOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks

Target Organs : Central nervous system

Symptoms : Loss of balance

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 20.03.2023

 5.1
 26.09.2023
 9371362-00007
 Date of first issue: 27.08.2021

Species : Dog
NOAEL : 2 mg/kg
LOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 27 Weeks

Target Organs : Skeletal muscle, Central nervous system

Symptoms : Loss of balance

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Species : Monkey
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Remarks : No significant adverse effects were reported

Simvastatin:

Species : Rat
NOAEL : 5 mg/kg
LOAEL : 30 mg/kg
Application Route : Oral

Exposure time : 14 - 104 Weeks

Target Organs : Liver, Testis, Musculo-skeletal system, Eye

Species : Dog LOAEL : 10 mg/kg Application Route : Oral

Exposure time : 14 - 104 Weeks
Target Organs : Liver, Testis, Eye

Species : Rabbit
NOAEL : 30 mg/kg
LOAEL : 50 mg/kg

Application Route : Oral

Target Organs : Liver, Kidney

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Starch:

Species : Rat

NOAEL : >= 2,000 mg/kg
Application Route : Skin contact
Exposure time : 28 Days

Method : OECD Test Guideline 410

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 5.1 26.09.2023 9371362-00007 Date of first issue: 27.08.2021

Ascorbic acid:

Species : Rat, male

NOAEL : >= 8,100 mg/kg

Application Route : Ingestion

Exposure time : 13 Weeks

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Sitagliptin:

Inhalation : Symptoms: upper respiratory tract infection, pharyngitis,

Headache

Ingestion : Symptoms: upper respiratory tract infection, nasopharyngitis,

Headache, Nausea, Abdominal pain, Diarrhoea

Simvastatin:

Skin contact : Remarks: May produce an allergic reaction.

Ingestion : Target Organs: Liver

Symptoms: upper respiratory tract infection, Headache, Ab-

dominal pain, constipation, Nausea Target Organs: Musculo-skeletal system

SECTION 12: Ecological information

12.1 Toxicity

Components:

Sitagliptin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 60 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 39

mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2

mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50 : > 150 mg/l

Exposure time: 3 h

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 5.1 26.09.2023 9371362-00007 Date of first issue: 27.08.2021

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 150 mg/l Exposure time: 3 h

Test Type: Respiration inhibition

Toxicity to fish (Chronic tox-

icity)

NOEC: 9.2 mg/l Exposure time: 33 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 9.8 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Simvastatin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 2.91 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 3.5 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 25

mg/l

Exposure time: 96 h

NOEC (Pseudokirchneriella subcapitata (green algae)): 25

mg/l

Exposure time: 96 h

Toxicity to microorganisms : EC50 : > 30 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 21 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Ascorbic acid:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 1,020 mg/l

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 20.03.2023

 5.1
 26.09.2023
 9371362-00007
 Date of first issue: 27.08.2021

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to microorganisms : EC50 : 140 mg/l

Exposure time: 16 h Method: DIN 38 412 Part 8

12.2 Persistence and degradability

Components:

Sitagliptin:

Biodegradability : Result: not rapidly degradable

Biodegradation: 39.7 % Exposure time: 28 d

Method: OECD Test Guideline 314

Stability in water : pH: 7

Hydrolysis: 50 %(401 d)

Method: OECD Test Guideline 111

Simvastatin:

Biodegradability : Result: rapidly degradable

Stability in water : Hydrolysis: 50 %(3.2 d)

Cellulose:

Biodegradability : Result: Readily biodegradable.

Ascorbic acid:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 97 % Exposure time: 5 d

Method: OECD Test Guideline 302

12.3 Bioaccumulative potential

Components:

Sitagliptin:

Partition coefficient: n-

log Pow: -0.03

octanol/water

Simvastatin:

Partition coefficient: n-

: log Pow: > 4.07

octanol/water

Ascorbic acid:

Partition coefficient: n-

octanol/water

log Pow: -1.85

19 / 24

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 5.1 26.09.2023 9371362-00007 Date of first issue: 27.08.2021

12.4 Mobility in soil

Components:

Sitagliptin:

Distribution among environmental compartments

log Koc: 4.37

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 5.1 26.09.2023 9371362-00007 Date of first issue: 27.08.2021

IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADR : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17) : Not applicable UK REACH Candidate list of substances of very high : Not applicable

concern (SVHC) for Authorisation

The Persistent Organic Pollutants Regulations (retained : Not applicable

Regulation (EU) 2019/1021 as amended for Great Brit-

ain)

21 / 24

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 20.03.2023

 5.1
 26.09.2023
 9371362-00007
 Date of first issue: 27.08.2021

Regulation (EC) No 1005/2009 on substances that de: Not applicable

plete the ozone layer

UK REACH List of substances subject to authorisation : Not applicable

(Annex XIV)

GB Export and import of hazardous chemicals - Prior : Not applicable

Informed Consent (PIC) Regulation

Control of Major Accident Hazards Regulations 2015 (COMAH)

Not applicable

Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H315 : Causes skin irritation.

H317 : May cause an allergic skin reaction.
H319 : Causes serious eye irritation.

H372 : Causes damage to organs through prolonged or repeated

exposure.

H411 : Toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Irrit. : Eye irritation
Skin Irrit. : Skin irritation
Skin Sens. : Skin sensitisation

STOT RE : Specific target organ toxicity - repeated exposure GB EH40 : UK. EH40 WEL - Workplace Exposure Limits

GB EH40 / TWA : Long-term exposure limit (8-hour TWA reference period)
GB EH40 / STEL : Short-term exposure limit (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regula-

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 20.03.2023

 5.1
 26.09.2023
 9371362-00007
 Date of first issue: 27.08.2021

tion (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sheet

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

Eye Irrit. 2	H319	Calculation method
Skin Sens. 1	H317	Calculation method
STOT RE 2	H373	Calculation method
Aquatic Chronic 3	H412	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 20.03.2023

 5.1
 26.09.2023
 9371362-00007
 Date of first issue: 27.08.2021

GB / EN